These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Does mycophenolate mofetil prevent extra-renal flares in systemic lupus erythematosus? Results from an observational study of patients in a single practice treated for up to 5 years. Posalski JD, Ishimori Ml, Wallace DJ, Weisman MH. Lupus; 2009 May; 18(6):516-21. PubMed ID: 19395453 [Abstract] [Full Text] [Related]
10. Mycophenolate mofetil in systemic lupus erythematosus: results from a retrospective study in a large monocentric cohort and review of the literature. Conti F, Ceccarelli F, Perricone C, Massaro L, Cipriano E, Pacucci VA, Truglia S, Miranda F, Morello F, Alessandri C, Spinelli FR, Valesini G. Immunol Res; 2014 Dec; 60(2-3):270-6. PubMed ID: 25468307 [Abstract] [Full Text] [Related]
12. Mycophenolate mofetil in the treatment of SLE and systemic vasculitis: experience at a single university center. Lourdudoss C, Vollenhoven Rv. Lupus; 2014 Mar; 23(3):299-304. PubMed ID: 24399811 [Abstract] [Full Text] [Related]
14. A national survey on current use of mycophenolate mofetil for childhood-onset systemic lupus erythematosus in Japan. Hara R, Miyazawa H, Nishimura K, Momoi T, Nozawa T, Kikuchi M, Sakurai N, Kizawa T, Shimamura S, Yasuda S, Hiromura K, Sada KE, Kawaguchi Y, Tamura N, Takei S, Takasaki Y, Atsumi T, Mori M. Mod Rheumatol; 2015 Mar; 25(6):858-64. PubMed ID: 26215483 [Abstract] [Full Text] [Related]
15. Mycophenolate mofetil in the treatment of systemic lupus erythematosus. Dall'Era M. Curr Opin Rheumatol; 2011 Sep; 23(5):454-8. PubMed ID: 21720247 [Abstract] [Full Text] [Related]
16. Can we identify who gets benefit or harm from mycophenolate mofetil in systemic lupus erythematosus? A systematic review. Mendoza-Pinto C, Pirone C, van der Windt DA, Parker B, Bruce IN. Semin Arthritis Rheum; 2017 Aug; 47(1):65-78. PubMed ID: 28325471 [Abstract] [Full Text] [Related]
17. Mycophenolic acid exposure and complement fraction C3 influence inosine 5'-monophosphate dehydrogenase activity in systemic lupus erythematosus. Mino Y, Naito T, Shimoyama K, Ogawa N, Kawakami J. Ann Clin Biochem; 2017 Jul; 54(4):490-494. PubMed ID: 27538768 [Abstract] [Full Text] [Related]
18. Tolerability of mycophenolate mofetil in patients with systemic lupus erythematosus. Riskalla MM, Somers EC, Fatica RA, McCune WJ. J Rheumatol; 2003 Jul; 30(7):1508-12. PubMed ID: 12858449 [Abstract] [Full Text] [Related]
19. Azathioprine and Mycophenolate Mofetil Adherence Patterns and Predictors Among Medicaid Beneficiaries With Systemic Lupus Erythematosus. Feldman CH, Collins J, Zhang Z, Xu C, Subramanian SV, Kawachi I, Solomon DH, Costenbader KH. Arthritis Care Res (Hoboken); 2019 Nov; 71(11):1419-1424. PubMed ID: 30354025 [Abstract] [Full Text] [Related]